Dr. Mohammed Ibn-Mas’ud, Danjuma
MBBS; MRCP (UK); FRCP (Edinburgh, UK) MMed Sci. Nephrology (Sheffield, UK); Doctorate in Clinical Pharmacology (Liverpool)
Dr Danjuma is currently a Consultant in Internal Medicine at HMC in Doha, Qatar and an Assistant Professor of Clinical Medicine at Weill Cornell Medicine Qatar, where I’m actively involved in a robust, purposeful, team-based innovation aimed at enhancing patient care and minimising clinical risk. I completed my undergraduate medical education at the College of Medical sciences, the University of Maiduguri, Nigeria in 1997. I left medical school as the overall best graduating Doctor with distinctions in Pharmacology, Physiology, and Human Anatomy. I subsequently obtained MRCP (UK) in 2006, dual certificate of completion of specialist residency training (CCST) in General internal medicine AND Clinical pharmacology, and therapeutics (Liverpool, UK) in 2012. Additionally, I have pursued clinical academic research training leading to the attainment of Masters in Nephrology in 2002 (Sheffield, UK), and lately Doctorate in Clinical Pharmacology in 2017 (University of Liverpool, UK) exploring the “determinants (including genetics) of adverse drug reactions. I have intimately been involved with the adverse drug reaction team at both the MRC centre for drug safety science, and Wolfson centre for personalised medicine both at the University of Liverpool, UK.
My active areas of research now revolves around the therapeutics utility of stratified medicine in determining drug response in patients with diabetes as well as reducing the burden of adverse drug reactions.
